KabuDo

NYSE: HCA · Health Care Facilities

HCA Healthcare

HCA Healthcare, based in Nashville, is one of the leading health care services companies in the United States. At the end of 2025 it operated 190 hospitals (179 general acute care, seven behavioral and four rehabilitation) plus 121 freestanding ambulatory surgery centers, 31 endoscopy centers and other outpatient facilities, with about 320,000 employees. It manages its hospitals in three operating groups (National, Atlantic and American). 2025 revenues rose 7% to $75,600 million and net income attributable to HCA to $6,784 million, or $28.33 per share. Managed care and other insurers paid about half of revenue, with Medicare and Managed Medicare another third. HCA returns cash through buybacks ($10 billion authorizations in 2025 and 2026) and a dividend raised to $0.78 per quarter in 2026.

Last updated

Analysis last edited: October 31, 2026 · Financial data fetched: October 25, 2026 03:39 (SEC EDGAR) · Source 10-K filed: February 10, 2026

Built on10-K FY2025 · filed 2026-02-1010-Q (quarter ended 2026-09-30) · filed 2026-10-29Proxy statement (2026)

Next update expectedAfter FY2026’s 10-K is filed (roughly 60–90 days after fiscal year end (sooner for larger filers)), financials and analysis will be refreshed.

01

At a glanceFrom SEC data

Eight headline measures, each placed among the companies covered on this site.

Revenue growth
8.0%

Higher than 47% of 372 non-financial companies

Average yearly growth over the years shown

Operating margin
—

Latest fiscal year (FY2025)

ROIC minus WACC
—

Return on capital above (or below) its estimated cost

Net debt ÷ EBITDA
—

Below 0 means more cash than debt

Cash conversion
1.86x

Higher than 66% of 349 non-financial companies

Operating cash flow ÷ net income

Dividend raises
5 of 5

Years the dividend per share rose, of the last 5

P/E today
16.5x

Latest close 2026-11-04; trailing 12 months to 2026-09-30

Beta
0.53

Above 1 = moves more than the market

Each marker shows where this company sits among the non-financial companies covered on this site, not all listed companies (left = lowest, right = highest). A high position is not automatically good — for net debt ÷ EBITDA, higher means more debt. Details and formulas are in the sections below and in How to read this.

02

Valuation todayFrom SEC data

Price-based measures at the latest close, next to the same measures at the last fiscal year-end.

Share price$496.81close on 2026-11-04

Market cap$111.59B

P/E today
16.5x

At FY2025 year-end: 16.5x

Earnings: trailing 12 months to 2026-09-30

P/B today
—

At FY2025 year-end: —

Book value at FY2025 year-end

EV/EBITDA today
—

At FY2025 year-end: —

EBITDA for FY2025

FCF yield today
6.9%

At FY2025 year-end: 7.3%

Free cash flow for FY2025

Dividend yield today
0.6%

Dividends per share for FY2025

“Today” uses the latest closing price (2026-11-04, Yahoo Finance daily closing prices) and shares outstanding at the last fiscal year-end. The rest of this page — including the financial table and ROIC vs. WACC — uses fiscal year-end prices. These are reference figures, not a judgment of whether the stock is cheap or expensive.

03

What changed since last earningsFrom SEC data

The latest reported quarter against the same quarter a year earlier, the balance sheet against the previous quarter-end, and what management said in its latest earnings release.

Quarter ended Sep 30, 2026.

  • Revenue↑ +3.6%$19.16B → $19.85B (vs. a year earlier)
  • Net income↓ −3.9%$1.64B → $1.58B (vs. a year earlier)
  • Diluted EPS↑ +4.5%$6.96 → $7.27 (vs. a year earlier)
  • Cash↓ −10.4%$1.01B → $908M (vs. previous quarter-end)
  • Long-term debt↓ −2.3%$45.83B → $44.77B (vs. previous quarter-end)

Source: Form 10-Q ↗ (SEC XBRL). Long-term debt is the tagged long-term debt figure and leaves out short-term borrowings.

From the earnings release of Oct 27, 2026.

Management outlook • Issued

Now expects full-year results in the upper half of its 2026 guidance ranges. Source sentence
The Company now believes its full year operating results will be in the upper half of its 2026 estimated guidance ranges previously issued on July 14, 2026.

Key changes

  • Net income down 3.9% to $1.579B. Source sentence
    Net income attributable to HCA Healthcare, Inc. declined 3.9 percent to $1.579 billion
  • Diluted EPS up 4.5% to $7.27. Source sentence
    Diluted earnings per share increased 4.5 percent to $7.27 per diluted share, and diluted earnings per share, as adjusted, increased 3.7 percent to $7.22 per diluted share
  • Same facility admissions up 2.7%. Source sentence
    Same facility admissions increased 2.7 percent and same facility equivalent admissions increased 3.0 percent

Written by AI. A line appears only if its figures and direction match the quoted sentence, which an automatic check confirms. Companies' outlooks are their own and may not be met. Read the release ↗

04

Company profileFrom SEC dataShow

Legal name
HCA Healthcare, Inc.
Headquarters
NASHVILLE, TN
Fiscal year end
12/31
Exchange & ticker
NYSE: HCA
Industry
Health Care Facilities
CIK
860730

Workforce (as of FY2025 year-end)

  • Employees

    320,000

Source: Form 10-K (FY2025) cover page and business description

05

Earnings calendarFrom SEC dataShow

When the company reports each quarter: the quarter-end date, the day results were released, and when the 10-Q or 10-K was filed.

Next report

Q4 FY2026

Quarter end: December 2026. In past years, Q4 results were released 24–30 days after quarter end (Jan 27, 2026; Jan 24, 2025; Jan 30, 2024). No date has been announced in the sources this site uses.

Reporting pattern

  • Fiscal year ends around December 31.
  • Reports four times a year: three quarterly reports (10-Q) and an annual report (10-K) for Q4.
  • Earnings releases came 23–30 days after quarter end over the last 12 quarters.
QuarterQuarter endedEarnings release (8-K)Report filed (10-Q / 10-K)
Q3 FY2026Sep 30, 2026Oct 27, 2026 (+27 days)Oct 29, 2026 10-Q (+29 days)
Q2 FY2026Jun 30, 2026Jul 24, 2026 (+24 days)Jul 28, 2026 10-Q (+28 days)
Q1 FY2026Mar 31, 2026Apr 24, 2026 (+24 days)Apr 29, 2026 10-Q (+29 days)
Q4 FY2025Dec 31, 2025Jan 27, 2026 (+27 days)Feb 10, 2026 10-K (+41 days)
Q3 FY2025Sep 30, 2025Oct 24, 2025 (+24 days)Oct 30, 2025 10-Q (+30 days)
Q2 FY2025Jun 30, 2025Jul 25, 2025 (+25 days)Aug 4, 2025 10-Q (+35 days)
Q1 FY2025Mar 31, 2025Apr 25, 2025 (+25 days)May 1, 2025 10-Q (+31 days)
Q4 FY2024Dec 31, 2024Jan 24, 2025 (+24 days)Feb 14, 2025 10-K (+45 days)
Q3 FY2024Sep 30, 2024Oct 25, 2024 (+25 days)Oct 31, 2024 10-Q (+31 days)
Q2 FY2024Jun 30, 2024Jul 23, 2024 (+23 days)Jul 29, 2024 10-Q (+29 days)
Q1 FY2024Mar 31, 2024Apr 26, 2024 (+26 days)May 2, 2024 10-Q (+32 days)
Q4 FY2023Dec 31, 2023Jan 30, 2024 (+30 days)Feb 16, 2024 10-K (+47 days)

Source: SEC EDGAR filing history. Release dates are the dates the earnings release was furnished to the SEC on Form 8-K (Item 2.02), which is normally the day results are announced. For a quarter whose 10-Q or 10-K isn’t filed yet, the date is the latest Item 2.02 8-K since the previous report, which may be a preliminary or other results-related update. Fiscal years are labeled by the calendar year in which they end.

06

Flagship products & servicesSite analysis

  • Hospitals

    General acute care hospitals

    179 general acute care hospitals offering medical, surgical, emergency and other services.

  • Hospitals

    Behavioral and rehabilitation hospitals

    Seven behavioral and four rehabilitation hospitals.

  • Outpatient

    Ambulatory surgery and endoscopy centers

    121 freestanding ASCs and 31 freestanding endoscopy centers.

From the Form 10-K, FY2025.

U.S., worldwide and country/regional share of flagship products/services

Only shares the company itself states (in its filings or press releases, sometimes citing a research firm) are shown. Scope and timing vary by figure — treat these as approximate.

  • Hospital services

    U.S. health care services

    U.S. share

    One of the leading

    Company-disclosed

    “HCA Healthcare, Inc. is one of the leading health care services companies in the United States.”

    Worldwide share

    —

    Not disclosed

Sources:

No percentage share is given.

07

Recent strategic focusSite analysis

Recent developments.

  1. 2025 results

    Revenues $75,600M (+7.1%); net income attributable to HCA $6,784M; EPS $28.33.

    Source: Form 10-K (FY2025)

  2. Q3 2026

    Revenues $19.849B (+3.6%); net income attributable $1.579B (−3.9%); diluted EPS $7.27 (+4.5%); same-facility admissions +2.7%. HCA repurchased 7.23M shares for $2.97B in the quarter and expects full-year results in the upper half of its guidance ranges.

    Source: Q3 2026 earnings release

  3. Capital return

    $10B buyback authorized in January 2026; quarterly dividend raised to $0.78.

    Source: Form 10-K (FY2025)

Capex ÷ D&A (FY2025)

1.40x

Well above depreciation — expansion-stage investment

formulacapital expenditures ÷ depreciation & amortization

e.g.$4,944M ÷ $3,523M = 1.40x

termsCapital expenditures (capex) · Depreciation & amortization (D&A)

M&A spend (6-year total)

$1.3B

Latest year: $397M

Cash-flow-statement spending on acquisitions, net of cash acquired

Where the money goes, over time

Unit: $M. Capex went from $2.84B in FY2020 to $4.94B in FY2025

  • Capex
  • M&A spend

formulacapital expenditures ÷ depreciation & amortization

termsCapital expenditures (capex) · Depreciation & amortization (D&A)

Source: each period's Form 10-K (SEC EDGAR). Latest: filed 2026-02-10

08

Key figures at a glanceFrom SEC data

FY2020–FY2025, 6 years.

Revenue (FY2025)

$75.6B

As reported in the 10-K

Revenue CAGR (5 years)

+8.0%▲favorable

formula(last-period revenue ÷ first-period revenue) ^ (1 ÷ years) − 1

e.g.($75,600M ÷ $51,533M) ^ (1÷5) − 1 = 8.0%

termsCAGR · ^ (exponent) · Revenue (net sales)

Operating margin (FY2025)

—

formulaoperating income ÷ revenue × 100

termsOperating income · Revenue (net sales)

ROE (FY2025)

—▼caution

6-year average: 656.3%

As reported in the 10-K

P/B (FY2025 end)

—

formulafiscal year-end closing price ÷ book value per share

termsP/B · BVPS

Period-end (fiscal year-end) value, not today's P/B

EV/EBITDA (FY2025 end)

—

formula(market cap + interest-bearing debt − cash and equivalents) ÷ (operating income + depreciation & amortization)

termsEV/EBITDA · Market capitalization · Interest-bearing debt · EBITDA · Depreciation & amortization (D&A)

Period-end (fiscal year-end) value, not today's multiple

  • ▲

    Revenue grew +8.0% a year over 5 years (strong growth)

    From $51.53B in FY2020 to $75.6B in FY2025. The annualized rate (CAGR) makes it possible to compare growth pace across companies of different sizes.

  • ▼

    Equity ratio is -9.9% (relatively heavy reliance on debt)

    The share of total assets funded by equity rather than debt. 50%+ is often read as low bankruptcy risk, though the right level varies by industry (real estate and leasing run lower, for instance).

  • ▲

    Free cash flow was positive in 6 of 6 years

    Operating cash flow minus capital expenditures: the cash left over after funding the business’s own investment, available for dividends, buybacks, acquisitions, or debt paydown. A negative year can mean heavy investment, or weak core earnings — worth distinguishing.

  • ▲

    ROE averaged 656.3% over 6 years (latest: —)

    How much profit was generated on shareholders’ equity. Roughly 10%+ is often cited as solid for a U.S. company, though this varies a lot by industry and capital intensity.

09

Business modelSite analysis

Operates acute care hospitals and outpatient facilities and is paid by commercial insurers, Medicare, Medicaid and patients for inpatient and outpatient services.

How money and goods flow at HCA Healthcare
  1. 01 what it draws on

    Inputs & resources

    • About 320,000 employees (incl. about 90,000 part-time and PRN)
    • 190 hospitals and outpatient centers
    • Affiliated physicians and nurses
  2. 02 what it does

    Activities

    • Inpatient and emergency care
    • Outpatient surgery, endoscopy and imaging
    • Behavioral and rehabilitation care
  3. 03 who it serves

    Customers

    • Patients covered by managed care and other insurers (48.9% of 2025 revenue)
    • Medicare and Managed Medicare (32.7%)
    • Medicaid and Managed Medicaid (12.7%)
  4. 04 how money comes in

    How it earns

    • Revenues $75,600M (2025)
    • Atlantic Group $24,709M, American Group $26,445M, National Group $21,278M

How the business makes money

  • International managed care and other insurers revenue was $1,864M in 2025.
  • Shareholders’ equity attributable to HCA is negative after large buybacks.
  • Board authorized $10B buyback programs in January 2025 and January 2026.

Government & regulation around the business

Non-market factors from the company’s filings: what governments and regulators fund, buy, set, approve or restrict, and which part of the flow above each one touches.

HCA’s volumes depend on Exchange subsidies and Medicare/Medicaid, and antitrust and expansion rules apply.

  • Government funding & tax credits

    Exchange subsidy expiry

    Expects effects from the expiration of enhanced premium tax credits at end-2025.

    Constrains the businessTouches: Customers

    Source: Form 10-K (FY2025)

  • Approvals & licenses

    Expansion rules

    Federal and state rules can limit its ability to expand.

    Constrains the businessTouches: Activities

    Source: Form 10-K (FY2025)

  • Trade & export rules

    Tariffs and trade rules

    Tariffs may affect its supply chain.

    Constrains the businessTouches: Inputs & resources

    Source: Form 10-K (FY2025)

Revenue by segment (FY2025)

Unit: $M — bar length = revenue, (%) = share of total company revenue

  • American Group

    26,445 (37%)
  • Atlantic Group

    24,709 (34%)
  • National Group

    21,278 (29%)

Source: Form 10-K (FY2025) — Segment information Operating-group revenues; other operations make up the rest of the $75,600M total.

10

Contract structureSite analysisShow

Short-term or spot sales carry different earnings quality than long-term or auto-renewing contracts — this shows how the company actually contracts with its customers.

11

Customers & suppliersSite analysis

Who the company sells to and buys from. Companies rarely name either, so named counterparties come only from the company's own filings and press releases; otherwise this lists the concentration figures the 10-K discloses.

Customers

Patients and their payers: commercial insurers, Medicare, Medicaid and self-pay.

Named by the company

No single customer is named.

Suppliers

Medical supply and pharmaceutical suppliers and group purchasing.

Named by the company

No supplier is named as material.

12

Competitors & peersSite analysis

Competitors the 10-K names, and the peer group the company itself chose in its proxy statement. Nothing here is this site's own pick.

HCA’s hospitals compete with other hospitals, including not-for-profit and government-owned facilities, specialty hospitals and outpatient providers; the 10-K names no specific competitors.

Competitors named in the 10-K

The 10-K names competitor categories only.

Peer group the company chose

Compensation peer group (24 companies), from the proxy statement. Peers are companies the board considers comparable — for example when setting executive pay — not necessarily direct competitors.

Health care services, insurance, pharmaceutical, medical supply and related companies with median 2024 revenue of $60.0B.

Source: Proxy statement (2026)

Company names link to this site’s analysis where one exists; “site ↗” opens the company’s own website.

13

Six years of financialsFrom SEC data

Each chart's axis holds a single unit (never mixing dollars, %, and $/share). The table's per-period header links to the filing the numbers came from.

Revenue over time

Unit: $M

Source: each period's Form 10-K (SEC EDGAR). Latest: filed 2026-02-10

Profit over time (operating → net)

Unit: $M

  • Pretax income
  • Net income

Source: each period's Form 10-K (SEC EDGAR). Latest: filed 2026-02-10

Margins over time

Unit: %

  • Operating margin
  • Net margin

formulaoperating income ÷ revenue × 100

termsOperating income · Revenue (net sales)

formulanet income attributable to the company ÷ revenue × 100

termsNet income (attributable to the company)

Cash flow over time

Unit: $M (below zero = cash went out)

  • Operating CF
  • Investing CF
  • Free CF

formulacash flow from operations − capital expenditures

termsFree cash flow (FCF) · Cash flow from operations (operating CF) · Capital expenditures (capex)

Source: each period's Form 10-K (SEC EDGAR). Latest: filed 2026-02-10

Financial stability & capital efficiency

Unit: %

  • Equity ratio
  • ROE

formulatotal equity ÷ total assets × 100 (as reported in the 10-K)

termsStockholders’ equity · Total assets

formulanet income ÷ average equity (beginning + ending, ÷2) × 100 (as reported in the 10-K)

termsNet income (attributable to the company) · Stockholders’ equity

Earnings per share (EPS) and dividend per share

Unit: $

  • EPS
  • Dividend per share

Source: each period's Form 10-K (SEC EDGAR). Latest: filed 2026-02-10

Line itemFY202010-K on EDGAR ↗FY202110-K on EDGAR ↗FY202210-K on EDGAR ↗FY202310-K on EDGAR ↗FY202410-K on EDGAR ↗FY202510-K on EDGAR ↗
Income statement ($M)
Revenue51,53358,75260,23364,96870,60375,600
Pretax income5,4309,8338,5807,7068,5239,832
Net income (attributable)3,7546,9565,6435,2425,7606,784
Revenue growthcalc(this year’s revenue − last year’s revenue) ÷ last year’s revenue × 100—14.0%2.5%7.9%8.7%7.1%
Net margincalcnet income attributable to the company ÷ revenue × 1007.3%11.8%9.4%8.1%8.2%9.0%
Balance sheet ($M)
Total assets47,49050,74252,43856,21159,51360,720
Total equity2,8921,489-731,060555-2,771
Interest-bearing debtSum of short- and long-term borrowings, notes/bonds payable31,00434,57938,08439,59343,03144,285
Equity ratio1.2%-1.8%-5.3%-3.2%-4.2%-9.9%
ROE656.3%—————
Cash flow ($M)
Operating CF9,2328,9598,5229,43110,51412,636
Investing CF-3,393-2,643-3,389-5,317-4,933-4,988
Financing CF-4,677-6,655-5,656-4,094-4,582-8,550
Free cash flowcalccash flow from operations − capital expenditures6,3975,3824,1274,6875,6397,692
Cash and equivalents1,7931,4519089351,9331,040
Per share & other
EPS ($)10.9321.1619.1518.9722.0028.33
BVPS ($)1.69-3.05-9.98-6.68-10.00-26.83
Dividend per share ($)0.431.922.242.402.642.88
Payout ratiocalcdividend per share ÷ diluted EPS × 1003.9%9.1%11.7%12.7%12.0%10.2%
P/E (x)15.112.112.514.313.616.5
P/B (x)calcfiscal year-end closing price ÷ book value per share97.59—————

P/B and EV/EBITDA use each period’s period-end (fiscal year-end) figures, not the current share price. Figures without a "calc" tag are as reported in the Form 10-K (the consolidated financial statements and, for older years, earlier 10-Ks), pulled automatically from SEC EDGAR. Where a later filing restated a prior period, the restated figure is used.

Last 8 quarters

Three-month figures from 10-Q filings. Change is versus the same quarter a year earlier. Newest quarter on top.

Quarter endedRevenueNet incomeDiluted EPS
2026-09-30$19.85B+3.6%$1.58B-3.9%$7.27
2026-06-30$20.23B+8.7%$1.7B+2.8%$7.62
2026-03-31$19.11B+4.3%$1.62B+0.6%$7.15
2025-12-31 †$19.51B+6.7%$1.88B+30.6%—
2025-09-30$19.16B$1.64B$6.96
2025-06-30$18.61B$1.65B$6.83
2025-03-31$18.32B$1.61B$6.45
2024-12-31 †$18.29B$1.44B—

† Fourth quarter = the 10-K’s annual figure minus the first three quarters; quarterly EPS isn’t derived this way because share counts change during the year.

14

Is ROIC above WACC?From SEC data

ROIC (the return on money invested in the business) above WACC (the cost of raising that money) means the company is creating value. WACC is an estimate, so its assumptions can be adjusted below.

Not enough data (operating income, equity, etc.) to compute ROIC/WACC.

15

What the price implies (DCF)From SEC data

A company's value can be written as its free cash flow divided by (cost of capital − perpetual growth). Working that backwards from the market's valuation shows how much growth the share price assumed — compared here with the company's actual past growth.

Growth the price implies (price on 2026-11-04)

1.8%

Perpetual FCF growth: g = r − FCF ÷ EV = 6.7% − 5.0%

Past FCF growth (FY2020–FY2025)

+3.8%

Compound annual rate, 5 years

Past revenue growth (FY2020–FY2025)

+8.0%

Compound annual rate, 5 years

Inputs (FY2025): free cash flow $7.69B (operating CF − capex); enterprise value $154.83B = market cap $111.59B (latest close, 2026-11-04) + debt $44.29B − cash and short-term investments $1.04B; r = WACC of 6.7% using this page’s default assumptions (β 0.53, risk-free 5.0%, market premium 5.5%).

Three WACC scenarios

The same calculation under cautious, base and optimistic cost-of-capital assumptions (risk-free rate fixed at the 10-year Treasury yield). Pick one to load it into the sliders below.

Try your own assumptions

V = FCF ÷ (r − g). It starts at the implied growth rate, where the theoretical value equals today’s enterprise value.

Theoretical enterprise value

$156.98B

FCF $7.69B ÷ (6.7% − 1.8%)

Theoretical ÷ actual enterprise value

1.01x

Above 1x: these assumptions value the business above the market did

How sensitive the answer is

Theoretical ÷ actual enterprise value for each combination of r and g.

g \ r4.7%5.7%6.7%7.7%8.7%
0%1.06x0.87x0.74x0.65x0.57x
2%1.84x1.34x1.06x0.87x0.74x
4%7.10x2.92x1.84x1.34x1.06x
6%——7.10x2.92x1.84x
8%————7.10x

A simplified model for seeing what the market price assumes, not a forecast or a target price. It treats free cash flow as growing at one constant rate forever; the result swings widely with small changes in r and g, and is undefined when g reaches r. Free cash flow here is operating cash flow minus capex, which is after interest — a full DCF of enterprise value would use cash flow before interest. Market cap uses the latest close (2026-11-04) × shares at fiscal year-end; free cash flow and WACC inputs are from the latest fiscal year.

16

Earnings qualityFrom SEC dataShow

The same reported profit can mean different things depending on whether it's backed by cash, driven by the core business, or the result of a one-off item. Four checks below.

  • ✓

    Operating CF ÷ net income: averages 1.79x

    Profit is backed by cash coming in.

  • ✓

    Accrual ratio (latest): -9.7%

    A small share of profit rests on accounting estimates.

  • ✓

    Days sales outstanding: 50 → 52 days

    No major slowdown in collecting on sales.

Operating CF vs. net income

Unit: $M — operating CF above net income means profit is backed by cash

  • Operating CF
  • Net income

formulacash flow from operations ÷ net income attributable to the company

termsCash flow from operations (operating CF) · Net income (attributable to the company)

formula(net income − operating CF) ÷ average total assets × 100

termsNet income (attributable to the company) · Cash flow from operations (operating CF) · Total assets

Source: each period's Form 10-K (SEC EDGAR). Latest: filed 2026-02-10

Receivables & inventory days

Unit: days — days grow when receivables or inventory build up faster than sales

  • Days sales outstanding

formulaaverage receivables (opening + closing ÷ 2) ÷ revenue × 365

termsAccounts receivable · Revenue (net sales)

formulaaverage inventory (opening + closing ÷ 2) ÷ cost of revenue × 365

termsInventory · Cost of revenue (COGS)

Worked examples (latest period)

formulacash flow from operations ÷ net income attributable to the company

e.g.$12,636M ÷ $6,784M = 1.86x

termsCash flow from operations (operating CF) · Net income (attributable to the company)

formulaoperating income ÷ income before income taxes × 100

termsOperating income · Income before income taxes (pretax income)

formulaaverage receivables (opening + closing ÷ 2) ÷ revenue × 365

e.g.($10,751M + $10,867M) ÷ 2 ÷ $75,600M × 365 = 52 days

termsAccounts receivable · Revenue (net sales)

formulaaverage inventory (opening + closing ÷ 2) ÷ cost of revenue × 365

termsInventory · Cost of revenue (COGS)

17

Who holds the sharesFrom SEC dataShow

How much of the stock large institutional investors report owning on SEC Form 13F, how much the directors and executive officers hold (and how much of the vote they control), and roughly how much is left for individual investors. Shown next to beta so the holder mix can be read alongside how much the stock swings.

Institutions, insiders and everyone else, 13F holdings as of 2026-06-30

“Everyone else” is what remains after shares reported on Form 13F and shares held by directors and executive officers: mostly individual investors, plus non-insider families or foundations and smaller or foreign institutions. The figures have different dates and 13F reports count some shares twice — read it as an approximate split.

Held by 13F filers
62.1%
Directors & officers (shares)
1.5%
Everyone else (est.)
36.4%

individuals and other non-13F holders

Directors & officers (voting power)
1.5%

no separate voting figure; shown as shares

Institutional-ownership rank
403 of 416

1 = most institutional; 97% of covered companies have more

Beta (adjusted)
0.53

above 1 = swings more than the market

  • 134.5M shares reported by 1,338 13F filers ÷ 216.5M shares outstanding on 2026-07-24. Option positions are excluded.
  • Directors and executive officers as a group, from the proxy statement’s beneficial-ownership table; includes shares they can acquire within 60 days.
  • A large “everyone else” share can still reflect a family, trust or foundation stake held outside the board; check the proxy statement’s 5% holders.

Sources: SEC Form 13F data set (holdings as of 2026-06-30) · Form DEF 14A filed 2026-03-13 (beneficial ownership table) · Form 10-Q cover page (shares outstanding as of 2026-07-24)

18

Strengths & weaknessesSite analysis

Strengths

  1. 1. Scale

    190 hospitals and a large outpatient network across its markets.

    Evidence: Form 10-K (FY2025)

  2. 2. Growing cash flow

    Operating cash flow rose from $9,431M (2023) to $12,636M (2025).

    Evidence: Form 10-K (FY2025)

  3. 3. Shareholder returns

    Dividend per share rose from $1.92 (2021) to $2.88 (2025) and $0.78 per quarter in 2026; share count fell from 339M (2020) to 225M (2025).

    Evidence: Form 10-K (FY2025)

Weaknesses

  1. 1. Leverage

    Interest-bearing debt of about $44.3B at end-2025 and negative equity attributable to HCA.

    Evidence: Form 10-K (FY2025)

  2. 2. Rising costs

    Other operating expenses rose to $5,043M in Q2 2026 from $3,793M, mainly Medicaid supplemental program expenses and professional fees, and to $4,548M (23.0% of revenue) in Q3 2026 from $4,161M.

    Evidence: Form 10-Q (quarter ended 2026-06-30); Q3 2026 earnings release

19

What draws investors to itSite analysis

Why the stock can look attractive to investors — each point paired with what has to hold for it to stay true, and the opposing view. This is this site's analysis, not a recommendation to buy or sell.

P/E (FY2025)

16.5x

Price at fiscal year-end ÷ diluted EPS

Dividend yield (FY2025)

0.62%

Dividends per share ÷ fiscal year-end price

Payout ratio (FY2025)

10%

Dividends per share ÷ diluted EPS

FCF yield (FY2025)

7.3%

(Operating CF − capex) ÷ market cap

  1. 1. Buybacks

    Share count fell about one-third from 2020 to 2025.

    What has to hold
    Cash flow stays strong.
    The other side
    Higher debt and negative equity.

    Evidence: Form 10-K (FY2025)

  2. 2. Dividend growth

    Quarterly dividend raised to $0.78 in 2026 from $0.72.

    What has to hold
    Earnings keep growing.
    The other side
    Reimbursement risk.

    Evidence: Form 10-K (FY2025)

Book value per share is negative because equity attributable to HCA is negative after buybacks. HCA does not report operating income. M&A for 2023–2025 is acquisitions of hospitals and health care entities.

20

ResilienceSite analysisShow

How well the company could absorb a bad year: its financial buffer, how its revenue and profit held up in the worst year on record, and what the 10-K says about the business's exposure to shocks. Figures and filing statements only — no overall rating.

1. Financial buffer (FY2025)

Cash & short-term investments ÷ debt due within a year

0.2x

$1.04B vs. $4.89B

Interest coverage (operating income ÷ interest expense)

Not disclosed

The income statement has no operating income line.

Free cash flow ÷ dividends paid

11.3x

$7.69B vs. $679M (FCF = operating CF − capex)

2. Worst year in the record, and the recovery

FigureWorst year-over-year changeBack to the prior level?
RevenueNo decline in the record—

Covers only the 6 fiscal years on record (FY2020–FY2025), which may not include a full recession — the worst year here isn’t necessarily how the company would fare in a severe downturn.

3. Business resilience (from the 10-K)

  • Profitable through 2020

    Net income attributable to HCA was $3,754M in 2020.

    Source: Form 10-K (FY2025)

22

Risks (including geopolitical)Site analysis

Starting from the 10-K's Risk Factors section, organized by category — geopolitical, currency, raw materials, regulatory, disaster, and more — with impact and likelihood assessed by this site.

Risk map

Vertical = impact on results, horizontal = likelihood. Upper right = most severe. Numbers match the list below (placement is this site’s own assessment).

Impact
High
1
Med
45
23
Low
LowMedHigh

Likelihood →

"Company disclosure" vs. "this site’s assessment"

The description and mitigation for each risk are this site’s summary of the 10-K’s "Risk Factors" section. Impact and likelihood are this site’s own assessment, not the company’s — where the company discloses its own likelihood assessment, that is noted in the summary.

Impact is judged from how large the affected business is relative to total revenue/profit, and from the risk’s track record of moving results in the past. Likelihood is judged from the filing’s wording and the current business environment (already occurring, or recurring). See the rating criteria.

  1. 1Law & regulation

    Reimbursement changes

    Company disclosure (summarized from the 10-K)
    Medicare and Medicaid payment changes, state budget pressure and federal actions could reduce revenue.
    Company’s stated mitigation
    Not stated in the filings.
    This site’s assessment
    Impact High / Likelihood High
  2. 2Labor & workforce

    Staffing

    Company disclosure (summarized from the 10-K)
    Competes for nurses and other professionals; salaries and benefits were 43.5% of 2025 revenue.
    Company’s stated mitigation
    Not stated in the filings.
    This site’s assessment
    Impact Med / Likelihood High
  3. 3Competition & technology shift

    Local competition

    Company disclosure (summarized from the 10-K)
    Competes with not-for-profit and government hospitals, specialty hospitals and ASCs.
    Company’s stated mitigation
    Not stated in the filings.
    This site’s assessment
    Impact Med / Likelihood High
  4. 4Law & regulation

    Investigations and litigation

    Company disclosure (summarized from the 10-K)
    Subject to government investigations, qui tam suits and malpractice claims.
    Company’s stated mitigation
    We continue to monitor all aspects of our business and have developed a comprehensive ethics and compliance program that is designed to meet or exceed applicable federal guidelines and industry standards.
    This site’s assessment
    Impact Med / Likelihood Med
  5. 5Disaster

    Natural disasters

    Company disclosure (summarized from the 10-K)
    Hurricanes such as Milton and Helene can disrupt facilities.
    Company’s stated mitigation
    We maintain property insurance coverage for claims in excess of deductibles and self-insured retention levels generally at $110 million per occurrence ($120 million effective January 1, 2026) to address the impact of physical damage to our facilities and for business interruption losses.
    This site’s assessment
    Impact Med / Likelihood Med

23

What changed in the risk factorsFrom SEC data

Paragraphs in the latest 10-K's Risk Factors that have little overlap with the year before, and paragraphs that were dropped.

New or substantially reworded (8)

  • As of December 31, 2025, our total indebtedness was $46.492 billion. Read more

    As of December 31, 2025, we had availability of $5.779 billion under our senior unsecured credit facility (after giving effect to all issued and outstanding letters of credit and our intention to maintain a minimum available borrowing capacity equal to the aggregate amount outstanding under the commercial paper program ($2.207 billion as of December 31, 2025)). Our indebtedness could have important consequences, including:

  • Our operations could be impaired by a failure in or breach of our information systems or those of third parties on whose systems our business relies.

  • Failure to effectively manage change associated with our technology, resiliency and other initiatives, including with respect to the implementation of a new EHR platform, may adversely affect our business, services and results of operations.

  • We utilize multiple integrated software and hardware operating systems across our operations, including in our hospitals. Read more

    Although we continually monitor these systems and strive to design our policies, programs and processes to preserve or manage these systems, such processes may not be effective and are subject to weaknesses and failures, including human error, data limitations, process delays, system outages, cybersecurity incidents or failed controls. Failure to effectively preserve or manage data accurately, timely and completely may adversely affect its quality and reliability and impair our ability to manage business needs, the provision of care, strategic decision-making and operations. We employ change management methodologies to plan, test and execute system upgrades and improvements. However, we cannot guarantee that our systems will operate as designed or that the…

  • We are implementing a new EHR platform across our facilities, which is complex and time-intensive. Read more

    Significant internal and external resources have been, and will continue to be, required for successful implementation, including resources to train colleagues. Complexity or delay in implementation may require substantial additional time and expense and divert management’s attention from other strategic priorities, which, in turn, could adversely affect our business, results of operations or financial condition. While we have taken steps intended to mitigate implementation risks, including staged deployments in certain facilities, there is no guarantee these mitigation efforts will be effective.

  • Further, we are executing financial resiliency initiatives designed to generate efficiencies and cost reductions that we expect will offset in part the adverse effects on our business from recent health care policy reforms, including the expiration of the enhanced premium tax credits and changes resulting from the FBA. Our ability to realize the benefits from these financial resiliency initiatives is subject to known and unknown risks and uncertainties, and failure to realize the expected benefits may have an adverse effect on our business and results of operations.

  • Legislation and administrative actions at the federal and state levels may also impact the funding for, or structure or administration of, the Medicaid program, including through changes to Medicaid supplemental payments and SDP arrangements. For example, the FBA includes significant health care policy reforms that are expected to result in Medicaid spending reductions and changes in administration of state Medicaid programs. Among other changes, the law makes significant changes to Medicaid financing mechanisms, including restrictions intended to reduce the federal matching funds received by state Medicaid programs, such as limitations on provider tax arrangements and SDP arrangements. The FBA requires HHS to revise regulations governing SDP arrangements to cap total payment rates paid by Medicaid managed care organizations for specified services, tying caps to Medicare payment rates…

  • flexibilities in the administration of state Medicaid programs. Read more

    For example, structural and other changes to Medicaid supplemental payment programs and SDP arrangements, both of which are subject to CMS approval, could result in our revenues from such payments being reduced or eliminated. Among other measures, states may divert funding for SDP arrangements from other payment programs or direct payments to a specific subset of providers, and we may not satisfy applicable criteria.

No longer in the text (4)

  • As of December 31, 2024, our total indebtedness was $43.031 billion. Read more

    As of December 31, 2024, we had availability of $3.486 billion under our senior secured cash flow credit facility and $4.500 billion under our senior secured asset-based revolving credit facility, after giving effect to letters of credit and borrowing base limitations. Our indebtedness could have important consequences, including:

  • Under our asset-based revolving credit facility, borrowing availability is subject to a borrowing base of 85% of eligible accounts receivable less customary reserves, with any reduction in the borrowing base that results in the borrowing base falling below the amount committed by the lenders thereunder commensurately reducing our ability to access this facility as a source of liquidity. In addition, under the asset-based revolving credit facility, when (and for as long as) the combined availability under our asset-based revolving credit facility and the revolving facility under our senior secured cash flow credit facility is less than a specified amount for a certain period of time or, if a payment or bankruptcy event of default has occurred and is continuing, funds deposited into any of our depository accounts will be transferred on a daily basis into a blocked account with the…

  • We may not be adequately reimbursed by third-party payers for services involving new technology.

  • As health care technology continues to advance, the price of purchasing new technology has significantly increased for providers. Read more

    Some payers have not adapted their payment systems to adequately cover the cost of new technology used to treat patients. If reimbursement from third-party payers for services involving new technology does not sufficiently cover our purchasing costs, we may be unable to acquire new technology. Even without sufficient third-party reimbursement, we may acquire or utilize new technology in order to treat our patients. In either case, our results of operations and financial position could be adversely affected.

7 more paragraphs differ; the filings below have the full text.

Matched automatically, quoted as filed, and may include rewording of an existing risk. Compares Item 1A of the 10-K filed Feb 10, 2026 ↗ with the 10-K filed Feb 14, 2025 ↗.

24

What to watch going forwardSite analysis

  • Medicaid supplemental payment programs and federal reimbursement changes.
  • Labor cost trends.
  • Pace of share buybacks against debt levels.
  • California waste disposal investigation.

25

Source documentsShow

This page's financial figures come from the Form 10-Ks listed below. Check the original filings for full detail.

Last updated

Analysis last edited: October 31, 2026 · Financial data fetched: October 25, 2026 03:39 (SEC EDGAR) · Source 10-K filed: February 10, 2026

Built on10-K FY2025 · filed 2026-02-10Proxy statement (2026)

Next update expectedAfter FY2026’s 10-K is filed (roughly 60–90 days after fiscal year end (sooner for larger filers)), financials and analysis will be refreshed.

This page is this site’s own analysis based on public information, and does not represent HCA Healthcare’s views. It is not a recommendation to buy or sell any security, and this site does not guarantee the accuracy of any figure or statement here. Always verify against the original source documents before making an investment decision.